A new injectable form of a crucial cancer drug is set to make a significant impact on patients in East Yorkshire and North Lincolnshire. According to BBC Lincolnshire, the Humber Health Partnership (HHP) is among the first NHS groups in the UK to introduce this innovative treatment, known as Keytruda, which is typically administered through a drip. This new method aims to free up more than 2,000 hours of hospital time each year across the region.
Samantha Pickering, the lead systemic anti-cancer therapy matron for the partnership, highlighted that around 288 existing patients would benefit from the reduced treatment time. She expressed her enthusiasm for the change, stating, "If we can make it even slightly less stressful for them, then absolutely we should be jumping on this as soon as we can."
Keytruda, or pembrolizumab, is an immunotherapy drug that assists the body's immune system in fighting cancer cells. Since its introduction in 2015, it has been administered via intravenous infusion, a process that can take over an hour in a hospital setting. The new injectable version is expected to cut this time down to just a couple of minutes, which will not only ease the burden on patients but also allow hospital staff to manage their time more effectively.
HHP serves several hospitals in the area, including Hull Royal Infirmary and Scunthorpe General Hospital. Starting from next week, the partnership anticipates administering the injection to its first patient. When the injectable form was released in March, there were 241 patients receiving pembrolizumab in Hull and an additional 47 in Grimsby and Scunthorpe. Pickering noted that this change could result in a remarkable 2,392 hours of chair time being freed up annually, enabling new patients to begin their treatment more quickly.
Rob Wells, a senior specialist pharmacist in cancer services at Castle Hill Hospital, added to the optimism surrounding the new treatment. He remarked, "It's going to free up so much of patients' lives. If you can reduce the chair time to minutes, it can overall only be a positive thing. Anything that can help the staff as well administering these treatments is a benefit, too."
Every year, approximately 14,000 cancer patients in England start a course of Keytruda, with many expected to transition to the injectable version. Depending on the type of cancer, the treatment will be administered every three weeks as a one-minute injection or every six weeks as a two-minute injection.
As this new treatment rolls out in our local hospitals, it presents a hopeful advancement in cancer care. Residents are encouraged to share their thoughts on how this change might impact the community and the lives of those affected by cancer.